Outcomes and Translational Sciences

Outcomes and Translational Sciences

Main Content

The Division of Outcomes and Translational Sciences will drive research and training (Translational Science Graduate Studies) in the laboratory, clinic, and community to establish best practices that optimize individual and population health & outcomes. Building on the experience of its members, the division will provide a platform for research collaborations to achieve these goals.

Pharmacoepidemiology: Real-world data on medication treatment outcomes (adherence, safety and effectiveness) is critical for improving population health outcomes. Our research in pharmacoepidemiology applies a combination of quantitative methods from epidemiology, biostatistics, data analytics, biomedical informatics, etc. to generate information on the adherence, safety and effectiveness of prescribed medication use in real-world settings.

Medication use and Outcomes: Real-world evidence to understand patient behaviors is critical for improving patient medication adherence and health outcomes.  Using a theory-based approach, we use qualitative, quantitative, and survey research methodologies to study these issues.  The goal of this research is to develop tools, interventions, and strategies that healthcare providers can use to engage patients in the medication use process, thereby optimizing medication use behaviors and outcomes.   

Cardiac Arrhythmias and Heart Failure: Understanding the mechanisms underlying the initiation of abnormal heartbeats (arrhythmia) and factors underlying impaired heart function (heart failure) are critical for development of safe and effective therapies. Our research spans expertise in structural and functional assessment from the nanoscale all the way to the clinic, to improving outcomes in patients with heart disease. 

Translational Cancer Pharmacology: Mechanistic studies and preclinical investigations to evaluate the role of solute carriers in cancer drug-induced toxicity profiles are critical to clinical translation to improve outcomes for cancer patients. Our collective research integrates preclinical models, transcriptomic/proteomic approaches, drug-drug interactions, drug transporters, pharmacokinetics, antitumor efficacy and biomarker identification to explore novel clinical intervention strategies to ameliorate the incidence and severity of debilitating side effects of cancer drugs.